Preview

Сандостатин и Сандостатин ЛАР при метаболических, нейроэндокринных и онкологических заболеваниях

https://doi.org/10.14341/2071-8713-5188

Полный текст:

Аннотация

Октреотид - это синтетический аналог гормона гипоталамуса соматостатина. Этот нейропепид широко распространен в органах человека и животных, как в ЦНС, так и на периферии, что определяет его потенциальные регуляторные функции. В 1987 году была получена первая регистрация препарата октреотида, препарат Сандостатин, для лечения акромегалии и карциноидных опухолей. В 1997 году появилась депо форма октреотида - Сандостатин ЛАР. В настоящее время препараты нашли свое применение во многих областях медицины при различных метаболических, нейроэндокринных и онкологических заболеваниях.

Об авторах

Екатерина Александровна Пигарова

Endocrinology Research Centre, Moscow


Россия


Лариса Константиновна Дзеранова

Эндокринологический научный центр, Москва


Россия


Список литературы

1. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10:213-225.

2. Adam N, Lim SS, Ananda V, Chan SP. VIPoma syndrome: challenges in management. Singapore Med J. 2010 Jul;51(7):e129-32.

3. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980 Jan;12(1):71-9.

4. American Gastroenterological Association. American Gastroenterological Association medical position statement: Short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124(4):1105-1110.

5. American Gastroenterological Association. American Gastroenterological Association medical position statement: Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6):1461-1463.

6. Barkun A, Bardou M, Marshall JK, et al. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003;139(10):843-857.

7. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223(4):327-35.

8. Bissonnette RT, Gibney RG, Berry BR, Buckley AR. Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review. Radiology. 1990 Mar;174(3 Pt 1):751-2.

9. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(68):77-9.

10. Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res. 2006;35:129-34.

11. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology. 2001;120(4):946-954.

12. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8.

13. Dalm VA, Hofland LJ, Lamberts SW. Future clinical prospects in somatostatin/cortistatin/ somatostatin receptor field. Mol Cell Endocrinol. 2008 May 14;286(1-2):262-77.

14. Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S87-94.

15. Fékété CN, de Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray JM. The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg. 2004 Mar;39(3):267-9.

16. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008 Jan 1;13:822-40.

17. Foxx-Orenstein A, Camilleri M, Stephens D, and Burton D (2003) Effect of a somatostatin analog on gastric motor and sensory functions in healthy humans. Gut 52: 1555-1561.

18. Fried M. Octreotide in the treatment of refractory diarrhea. Digestion. 1999;60 Suppl 2:42-6.

19. Gross M, Schiemann U, Muhlhofer A, Zoller WG. Meta-analysis: Efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy. 2001;33(9):737-746.

20. Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2010;2:CD008370.

21. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21(6):1052-1061.

22. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004 Feb;89(2):667-74.

23. Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology. 1995;109(4):1289-1294.

24. Krejs GJ. VIPoma syndrome. Am J Med. 1987;82:37-48.

25. Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, et al. (2006) A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 30: 331-341.

26. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, and Xiong X (2003) Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 88: 2586-2592.

27. Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, Li H, Hudson MM, Heideman RL, and Kun LE (1999) Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 135(Pt 1): 162-168.

28. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68.

29. Muehlbauer PM, Thorpe D, Davis A, Drabot R, Rawlings BL, Kiker E. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clin J Oncol Nurs. 2009 Jun;13(3):336-41.

30. National Comprehensive Cancer Network (NCCN). Neuroendocrine tumors. Clinical Practice Guidelines in Oncology. Version 1.2005. Jenkintown, PA: NCCN; 2005.

31. Norton JA, Levin B, Jensen RT. Cancer of the endocrine system. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 4th Ed. Philadelphia, PA: J.P. Lippincott Co;1993:1333-1417.

32. Peeters M, Van den Brande J, Francque S. Diarrhea and the rationale to use Sandostatin. Acta Gastroenterol Belg. 2010 Jan-Mar;73(1):25-36.

33. Pless J. The history of somatostatin analogs. J Endocrinol Invest. 2005;28(11 Suppl International):1-4.

34. Plöckinger U, Gustafsson B, Ivan D, Szpak W, Davar J; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography. Neuroendocrinology. 2009;90(2):190-3.

35. Rahier J, Guiot Y, Sempoux C. Morphologic analysis of focal and diffuse forms of congenital hyperinsulinism. Semin Pediatr Surg. 2011 Feb;20(1):3-12.

36. Ramage JK, Davies AHG, Ardill J, et al.; UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl IV):iv1 - iv16.

37. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63.

38. Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23-34.

39. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68(1):206-216.

40. Stephen AE, Hodin RA. Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am. 2006 Jul;15(3):497-510.

41. Strowski MZ, Blake AD. Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol. 2008 May 14;286(1-2):169-79.

42. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998 Oct;83(10):3419-3426.

43. Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA, and Goldstone AP (2004) Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 89: 4162-4165.

44. Wade AN, Cheng G, Teitelbaum U, Patel AA, Alavi A, Rickels MR. Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan. Pancreas. 2011 Jan;40(1):173-5.

45. Wang XP, Norman MA, Brunicardi FC. Somatostatin receptors and autoimmune-mediated diabetes. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):15-30.

46. Wass JA, Lytras N, Besser GM. Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly. Scand J Gastroenterol Suppl. 1986;119:136-140.


Для цитирования:


Пигарова Е.А., Дзеранова Л.К. Сандостатин и Сандостатин ЛАР при метаболических, нейроэндокринных и онкологических заболеваниях. Ожирение и метаболизм. 2011;8(1):26-30. https://doi.org/10.14341/2071-8713-5188

For citation:


Pigarova E.A., Dzeranova L.K. Sandostatin i Sandostatin LAR pri metabolicheskikh, neyroendokrinnykh i onkologicheskikh zabolevaniyakh. Obesity and metabolism. 2011;8(1):26-30. (In Russ.) https://doi.org/10.14341/2071-8713-5188

Просмотров: 23


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)